Versiti’s Comprehensive Center for Bleeding Disorders provides accessible, personalized care for patients with bleeding and clotting disorders. As southeastern Wisconsin's only federally funded Hemophilia Treatment Center, our board-certified hematologists lead multidisciplinary teams dedicated exclusively to conditions like hemophilia, von Willebrand disease, platelet function disorders, and thrombophilia. 

Specialized Expertise

Board-certified hematologists focusing exclusively on bleeding and clotting disorders

Gene Therapy Center

One of the nation's first centers delivering HEMGENIX gene therapy for hemophilia B

Comprehensive Support

Multidisciplinary teams addressing medical, emotional, and practical needs

HEMGENIX is an FDA-approved gene therapy for adults with hemophilia B who currently use factor IX prophylaxis therapy, have experienced life-threatening bleeding, or have repeated serious bleeding episodes. Through a single intravenous infusion, HEMGENIX delivers a functional factor IX gene to liver cells, enabling the body to produce its own clotting factor. Clinical studies demonstrate that 94 percent of patients receiving HEMGENIX can discontinue regular factor IX infusions.

Lynn Malec MD, MSc

Program Director
Versiti Comprehensive Center for Bleeding Disorders and Pharmacy

"We partner with patients through a transformative journey. Gene therapy requires sophisticated clinical judgment, comprehensive patient education, and meticulous long-term follow-up. At The Comprehensive Center for Bleeding Disorders, we've built our program around these principles, ensuring every patient receives the expert, coordinated care that makes transformation possible."

"From 2014 to 2019, I endured four ankle surgeries because of advanced arthritis from hemophilia B," said Cody Gunst, a CCBD patient. "If gene therapy had existed then, I wouldn't have two fused ankles now. But this treatment changed everything that came after."

Before gene therapy, Cody required approximately four factor infusions per month — vigilance that shaped every aspect of daily life. Within 60 days of receiving HEMGENIX, Cody’s factor IX levels increased from less than 1 percent to more than 12 percent.

Bleeding and clotting disorders require specialized expertise that goes beyond general hematology. At Versiti CCBD, our board-certified hematologists dedicate their practice exclusively to these complex conditions, developing the nuanced clinical judgment necessary for optimal diagnosis and treatment. This specialization means we recognize subtle presentations, anticipate complications, and personalize treatment.

We recognize that these conditions affect entire families, not just individual patients. We provide education, support, and resources for parents, siblings, partners, and caregivers, recognizing that family well-being has a direct impact on patient outcomes. Whether you're navigating a new diagnosis, managing complications, planning for surgery or exploring cutting-edge treatments like gene therapy, our team brings both sophisticated clinical knowledge and genuine partnership to every interaction.